N N dimethyltryptamine - Psilera
Alternative Names: DMT intranasal - Psilera; DMT patch - Psilera; N,N-dimethyltryptamine - PsileraLatest Information Update: 28 Apr 2026
At a glance
- Originator Psilera
- Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Neuropsychotherapeutics; Small molecules; Tryptamines; Vascular disorder therapies
- Mechanism of Action 5-HT1 serotonin receptor modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychiatric disorders; Social phobia
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for preclinical development in Psychiatric-disorders in USA (Intranasal)
- 28 Apr 2026 No recent reports of development identified for preclinical development in Social-phobia in USA (Transdermal, Patch)
- 14 Sep 2022 Psilera receives patent allowance for DMT and psilacetin transdermal patch formulations in USA